These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prognostic value of (99m)Tc-pertechnetate thyroid scintigraphy in radioiodine therapy in a cohort of Chinese Graves' disease patients: a pilot clinical study.
    Author: Hou H, Hu S, Fan R, Sun W, Zhang X, Tian M.
    Journal: Biomed Res Int; 2015; 2015():974689. PubMed ID: 25879041.
    Abstract:
    OBJECTIVES: This study is to assess the prognostic value of (99m)Tc-pertechnetate thyroid scintigraphy for predicting the outcomes of fixed low dose of radioiodine therapy (RIT) in a cohort of Chinese Graves' disease (GD) patients. MATERIALS AND METHODS: This is a retrospective study of GD patients who received RIT with a single dose of radioiodine (5 mCi). All the patients received (99m)Tc-pertechnetate thyroid scintigraphy prior to RIT. Thyroid mass, (99m)Tc-pertechnetate uptake, gender, age at diagnosis, duration of the disease, ophthalmopathy, and serum levels of FT4, FT3, TT4, and TT3 prior to RIT were analyzed as potential interference factors for outcomes of RIT. RESULTS: One hundred and eighteen GD patients who completed RIT were followed up for 12 months. The outcomes (euthyroidism, hypothyroidism, and hyperthyroidism) were found to be significantly associated with thyroid mass and (99m)Tc-pertechnetate uptake. Patients with thyroid mass ≤ 40.1 g or (99m)Tc-pertechnetate uptake ≤ 15.2% had higher treatment success. CONCLUSIONS: A fixed low dose of 5 mCi radioiodine seems to be practical and effective for the treatment of Chinese GD patients with thyroid mass ≤ 40.1 g and (99m)Tc-pertechnetate uptake ≤ 15.2%. This study demonstrates (99m)Tc-pertechnetate thyroid scintigraphy is an important prognostic factor for predicting the outcomes of RIT.
    [Abstract] [Full Text] [Related] [New Search]